Capital Flow Monitor · Sponsors · CIK 1852950
Enlaza Therapeutics, Inc.
11099 NORTH TORREY PINES ROAD, STE. 280, LA JOLLA, CA, 92037 · 858-348-2180
Pharmaceuticals · Corporation· inc. DELAWARE true 2020
Fit score
—
Offering
$15.0M
Sold
$15.0M
% sold
100.0%
Investors
1
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2025-09-11 | D ·current | 506(b) | $15.0M | $15.0M | 100.0% | 1 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- Sergio Duron — Executive Officer / Director, La Jolla, CA
- Sanford Madigan — Executive Officer, La Jolla, CA
-
Tighe Reardon — Executive Officer, La Jolla, CA
1 other raise
- AeroRx Therapeutics, Inc. $10.4M of $20.8M · 50.0%
- Jay Lichter — Director, La Jolla, CA
-
Shelley Chu — Director, La Jolla, CA
2 other raises
- Triana Biomedicines, Inc. $120.1M of $120.1M · 100.0%
- Odyssey Therapeutics, Inc. $214.0M of $214.0M · 100.0%
- James Topper — Director, La Jolla, CA
- Marcos Milla — Director, La Jolla, CA
-
Stephen Squinto — Director, La Jolla, CA
5 other raises
- 270 Healthcare Growth Fund I LP $113.9M of —
- 270 Healthcare Growth Fund I (LUX) SCSp-RAIF $113.9M of —
- 270 Life Sciences Private Capital Fund II (US) LP $0 of —
- 270 Life Sciences Private Capital Fund II (Cayman) LP $0 of —
- Averna Therapeutics Inc. $85.0M of $85.0M · 100.0%
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.